Nonhuman Primate Reagent Resource

The Nonhuman Primate Reagent Resource is funded by the National Institutes of Health to facilitate the optimal use of nonhuman primate models in biomedical research. The resource develops and maintains nonhuman primate reference cell lines and immunoglobulins, and is developing anti-Ig reagents for macaque monkeys and other primate species.

More information about this resource is available at Nonhuman Primate Reagent Resource

Main Areas of Focus

  • To facilitate the optimal use of nonhuman primate models in biomedical research by identifying, developing, characterizing, and producing reagents for monitoring or modulating immune responses.
  • To distribute unique, non-human primate-specific antibodies for in vitro diagnostics.
  • To develop and produce primate recombinant antibodies for in vivo cell depletion or modulating immune responses.


  • Commercial antibodies
  • Resource reagents


  • Protocols
  • Operating procedures
  • Technical notes

Collaboration Opportunities

  • Researchers can suggest a reagent, submit additions or corrections to reaction data, or participate in the Nonhuman Primate Immunology Quality Assessment Program.

Who Can Use This Resource

  • Reagents developed through this resource are available to all scientists utilizing nonhuman primate models with priority given to U.S. federally-funded investigators.
  • To register with the NIH Nonhuman Primate Reagent Resource, you must be a Principal Investigator, Laboratory Director, or equivalent (public or academic institution), or a Director of Research or equivalent (private or for-profit institution).

How To Get Started

  • Registrants must submit the signed registration form.
  • Most reagents for in vitro diagnostics are provided at no cost in limited quantities.
  • Reagents for in vivo use are provided at the cost of production.
  • Requesters are required to pay all shipping costs by establishing an account with an overnight shipping company.

Learn more about eligibility and how to get started.